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Abstract
Hepatitis B infection is a major public health problem caused by hepatitis B virus
(HBV). Factors associated with host immunity such as (HBV specific T- and/or B-
cell) production and antigen presentation failure and viral determinants such as the
HBV genotypes and their evolving variants, have largely contributed to and justified
variations that occur in the HBV surface gene. Hepatitis B surface gene mutations
may influence the accuracy of the results obtained with currently used serological
diagnostic tests and may represent a great risk for the community, since neither
hepatitis B vaccines nor hepatitis B immunoglobulin will prevent the infection by
HBV. Out of 96 published papers from (1988 till 2016) downloaded from Google
scholar and PubMed and evaluated according to the relevance of scientific data for the
surface gene mutations of hepatitis B virus then52 papers of themwere selected and
included in this study, then we reviewed and evaluated the current published papers
about the surface gene mutations worldwide in which G145R represents the most
common hepatitis B surface gene mutation reported in the literature. Furthermore,
we reviewed their clinical implications and their impact on hepatitis B vaccination and
treatment.
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عدوى التهاب الكبد الفيروسى الوباىئ هي مشكلة صحية عامة رئيسية ناجمة عن فيروس 
التهاب الكبد الوباىئ. العوامل المرتبطة بحصانة المضيف مثل انتاج الخاليا التائية والبائية 
مثل  الفيروسية  ومحددات  المستضد  تقديم  وعدم  الوباىئ  الكبد  لفيروس  المحددة 
له، ساهمت إىل حد كبير وبررت  المتطورة  والمتغيرات  الوباىئ  الكبدي  المورثات اللتهاب 
االختالفات التي تحدث يف الجين لسطح هذا الفيروس. الطفرات التى تحدث للمستضد 
السطحي لفيروس التهاب الكبد الوباىئ قد تؤثر على دقة النتائج التي يتم الحصول عليها 
ىف اختبارات التشخيص المصلية المستخدمة حاليا وقد تمثل خطرا كبيرا على المجتمع، 
العدوى عن  تمنع  الوباىئ  الكبد  التهاب  لفيروس  مناعية  غلوبولينات  أو  لقاحات  ال  حيث 
طريق هذا الفيروس. من أصل ٩٦ من األبحاث المنشورة ىف الفترة (١٩٨٨ حتى ٢٠١٦) تم 
تحميلها من باحث جوجل والبيب ميد تم تقييمها وفقا ألهمية البيانات العلمية للطفرات 
هذه  يف  وادرجت  منها  ورقة   ٥٢ اختيار  تم  الوباىئ  الكبد  التهاب  فيروس  لسطح  الجينية 
الجينية لسطح  الطفرات  الحالية حول  المنشورة  األوراق  الدراسة، ثم استعرضنا وقييمنا 
فيروس التهاب الكبد الوباىئ يف جميع أنحاء العالم والتى مثل فيها الجين  G١٤٥R  الطفرة 
يف  ذكرت  التى  الوباىئ  الكبد  التهاب  فيروس  لسطح  الجينية  الطفرات  من  شيوعا  األكثر 
ضد  والتطعيم  العالج  على  وأثرها  السريرية  آثارها  استعرضنا  ذلك،  على  وعالوة  األدب. 
التهاب الكبد الوباىئ.
1. Introduction
Hepatitis B is considered a life -threatening liver infection caused by hepatitis B virus.
It affects about 350 million people around the world and it is associated with high risk
of liver cirrhosis and hepatocellular carcinoma (HCC) [1]. Chronic hepatitis B infection
is considered as an important healthcare problem worldwide due to the significant
morbidity and mortality as well as being the cause of at least 50% of worldwide cases
of hepatocellular carcinoma and approximately 30% of liver cirrhosis [2]. According to
World Health Organization (WHO)more than 780,000 deaths occur worldwide annually
due to chronic complications of HBV associated liver disease [3]. The prevalence of HBV
carriers varies from 0.1% to 2% in low prevalence areas (United States and Canada,
Western Europe, Australia and New Zealand followed by 3% to 5% in intermediate
prevalence areas (Mediterranean countries, Japan, Central Asia, Middle East, and Latin
and South America) and 10% to 20% in high prevalence areas (Southeast Asia, China,
sub-Saharan Africa) [4].The seroprevalence of HBsAg in central Sudan is 17.5% [5].
HBV genome is a circular double stranded DNA of full length negative strand (3020
– 3320) and incomplete positive strand (1600 – 2800). It is composed of four partially
overlapping open reading frames (S, C, P and X) [6]. The S ORF encodes the surface
envelope protein of the virus (HbsAg) and can be subdivided into pre S1, preS2 and
S regions. As illustrated in Figure 1, the core gene (C gene) is divided into pre core
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and core regions where P gene (polymerase protein) is about 800 amino acids that
is divided into three domains. The X ORF protein domain (HbxAg) is involved in signal
transduction, DNA repair and transcriptional activation. Themechanism of HbxAg is not
completely understood but it may contribute to oncogenic activity of HBV [7]. Studies
suggested that there are a lot of virus genotypic variants and associated spectrum of
pathogenicity. Mutations in the S gene region occur under the selection of passive or
active immunoprophylaxsis and antiviral treatment or spontaneously [8].
The aim of this review was to highlight the most common mutations of HBV surface
gene and their clinical impacts.
2. Material and Methods
PubMed (www.ncbi.nlm.nih.gov) and Google scholar was searched with keywords
like “HBV”, “Hepatitis B virus”, “Hepatitis B virus surface gene mutations” and related
words, to finalize this review article. Ninety-six research and review articles were
selected. The selection criteria, of these research and review articles, were to include
the data which represent the global burden of s gene mutations. The exclusion criteria
were irrelevant scientific data. Finally, 52 papers selected and included in this study.
This review done during the period of 4 moths from Sep – Dec 2016.
2.1. Host Immune Response to HBV
Innate immunity eventually plays a role immediately after infection to limit the virus
multiplication and initiates the development of an adaptive immune response. Innate
host responses during the establishment of viral infections are mainly characterized
by the production of cytokines such as type 1 interferon (IFN)a/b and the activation
of natural killer (NK) cells. Production of type 1 IFNs can be induced directly by virus
replication via cellular mechanisms that detect the presence of viral RNA or DNA. NK
cells are activated by the recognition of stress-induced molecules and/or the alteration
of the quantity of major histocompatibility complex (MHC) class I molecules on the
surface of infected cells [9]. In adaptive immune response the antigen presenting cells
kupffer cells and dendretic cells responsible for the activation of HBV specific T cells
and production of interleukin 12(IL12) and TNF a, which induce IFN g production and
proliferation of CD8+ T cells which is the main effector in HBV clearance. In contrast
depleted CD8+ T cells in acutely infected individuals associated with the persistence of
HBV infection. The synergistic effect of cytokines and cytolytic activity of CD8+ T cells
allows for clearance of the virus without progressive liver damage and is consistent
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with viral and lymphocyte kinetics noticed in chimpanzees following acute HBV infec-
tion. Activated T-helper cell type 2 (Th2) CD4+ T-cells shown to induce B-cell production
of HBsAb, HBcAb and HBeAb in patients undergone HBV clearance [10, 11].
2.2. Virology and Genotypes
The HBV genome is a relaxed double-stranded circular DNAmolecule of 3.2 kb in length
[12]. It is classified into ten genotypes (A-J) that are scattered at different geographical
areas and each has specific clinical outcome. Genotyping is usually done using different
techniques such as line probe assay, genotype specific polymerase chain reaction and
restriction fragment length polymorphism [13]. Acute infection with genotype D is
considered as the main cause of acute liver failure than other genotypes [14] while
genotype A appears to have more favorable outcome than genotype D [15]. Genotype
C appears to have a significantly higher viral load than genotype B [16].
2.3. HBV Life Cycle
The replication process started with the entry of the HBV into the hepatocytes, then
the virion undergoes uncoated process and transported to the nucleus in which RC
DNA is converted into covalently closed circular DNA (cccDNA), cccDNA is transcribed
into subgenomic RNA (sgRNA) and pregenomic RNA (pgRNA) [17, 18]. The subgenomic
transcriptis used for the translation of envelope protein and X protein. The pgRNA is
used as a template for reverse transcription, translation of HBcAg and HBV Pol [19]. In
the cytoplasm the pgRNA is undergo reverse transcription to a nucleocapsid contain
DNA which is enveloped to be secreted as progeny virion through the endoplasmic
reticulum [20].
2.4. Epidemiology and Clinical Infection
The geographical distribution of HBV genotypes and HBsAg is as follows; Genotype A
is found in North America and northwestern Europe, genotypes B and C are found in
East Asia, genotype D is highly prevalent in the Mediterranean and the Middle East,
genotype E identified in West Africa, genotypes F and H are most prevalent in Central
and South America, and genotype G is found in the United States and Europe [21, 22]. In
2008 scientists isolated genotype I and the genotype J from Japanese patients [23, 24].
HBV is transmitted by exposure to infected blood or other body fluids. HBV trans-
mission has been reported with several forms of human contact such as mother to
child, household, sexual, needle stick and occupational/health care related. The highest
concentrations of infectious HBV are found in blood and serum. However, other body
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Figure 1: HBV genome showing open reading frames, major RNA transcripts and the regulatory elements
of the virus [19]. With permission from Prof Stephen locarnini.
fluids, such as semen and saliva, are also infectious [25]. HBV infection may result in
subclinical or asymptomatic infection, acute self-limited infection, or fulminant hepati-
tis requiring liver transplantation. People infected with HBV can develop chronic HBV
infection, which may lead to cirrhosis or hepatocellular carcinoma, the likelihood that
newly infected individuals will develop chronic HBV infection is related to their age at
the time of infection [26].
2.5. Hepatitis B Surface Antigen (HBsAg)
Hepatitis B surface antigen is a complex macromolecular structure that provides the
envelope protein of HBV, it is composed of 75% proteins and 25% carbohydrates
and host derived lipids. HBsAg produced during the infection of hepatocytes in the
form of lipoprotein of 22nm diameter. The HBV envelop proteins composed of Pre-
S1, Pre-S2 and S. The S protein, which codes for the S gene which is made up of 226
amino acids and is the main component of the viral envelop protein [27]. The three
envelop proteins can be translated as L (large), M (middle) and S (small) or collectively
HBsAg. Within the later the site between the aa 100-160 termed as major hydrophilic
region (MHR). This region comprised of aa 99-160 refers to ”a” determinant region.
MHR proposed to have two major loops and one minor loop which defined by some
disulphide bridge that join the epitope cluster for which majority of anti HBs directed
are against the epitope between aa 107-137 or (138), 139-147 or(149) and 121-124 [28].
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The ”a” determinant is considered as the main neutralizing epitope and its common in
all HBV genotypes, for this reason the anti HBs against the ”a” determinant are widely
protective against reinfection by HBV [29]. Changes in the conformation which can
successively lead to failure of binding of neutralizing antibodies may develop due to
amino acid substitutions within the” a” determinant [30]. Mutations in HBV occur due
to low fidelity of polymerase, high replication rate and overlapping reading frames. The
pre-S1/S2/S ORFs codes for three envelope proteins (large, middle and small) which
are responsible for virus assembly and attachment to hepatocytes. L protein pre-S1
domain (amino acids 21–47) is the substrate for viral receptor attachment; M protein
(pre-S2 domain) function is not well understood and, finally, S protein (S domain) is the
HBsAg. Mutation in HBV is either vaccine induced or drug induced and these mutations
can lead to occult hepatitis B infection, HBV reactivation and reinfection. Also it may
lead to diagnostic assay failure [31]. HBsAg contains the epitope for ”a” determinant
region between the amino acid residue 99- 169 and amino acid changes in this site
that lead to mutations that escape the immune response that provided by the vaccine
[32].
2.6. Mutations in HBV Genes
Several published studies suggested that hepatitis B virus (HBV) mutants must be
considered in occult HBV infection (OBI) which is characterized by the presence of
HBV infection without detectable HbsAg. However, it is not known how widespread
these mutants are and how they change the course of liver diseases. Jin lin hou et
al. studied 2,565 individuals with chronic hepatitis B infection, hemodialysis patients,
blood bank donors and cryptogenic liver cirrhosis. They found that 51 of them had
occult hepatitis B infection and 43% of them had mutations in the MHR region includes
the following Q101K, T115A, K122N, T123A, T126N, Q129N, G130R, T131I, M133T, F134L,
C138Y, K141E, P142S, G145R, N146S, and C147F/R1 [33]. The existence of occult HBV
patients caused by HBsAg mutants has implications for their possible transmission
role through sexual contact and by blood transfusion. Naturally occurring mutations
may envolve the polymerse gene as the tyrosine –methionine-aspartate-aspartate
(YMDD-motif) mutations can occur spontaneously without using of antiviral therapy.
Accumulation of base mismatch due to the natural features of viral polymerase might
be the cause of this mutation [34].
2.7. Vaccine Escape Mutants
HBV vaccine is a recombinant DNA vaccine that contains HBsAg genetically engineered
from the yeast Sacchromyces Cerevisiae. It provides seroprotection rate of 85 – 100 %
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that seen one month after the last dose of vaccine and it confers immunity for at
least 10 years [35]. Vaccine escape mutants at the ”a” determinant region occurred
under selection pressure of HBV vaccine administration or hepatitis B immunoglobulin
(HBIG) or both [36]. The first HBsAg gene mutation was observed in vaccinated Italian
child who was presented with both HBsAg and anti HBs. Gene sequencing showed
substitution in which glycine replaced by arginine at site 145(G145R mutant) [37]. This
G145R represents the most prevalent HBsAg mutation in the literature. It is addressed
as a public health concern because of its capability of escaping the immune system
and it found in immunocompromised patients and infant of HBeAg positive mother
with prevalence of 3.1%. It may accompany other mutations such as T126I-T131A-
C139Y-E/D144G, T126I-M133L, and P120Q-T126I in 37.5% [38]. Ngui et al. studied 17
HBV-infected mother and infant pairs as the infants became infected with HBV inspite
of immunoprophylaxis administration. The S gene was sequenced for all patients and
15 mother/infant pairs showed complete concordance, while in the other two pairs
showed the following: in one infant there were three nucleic acid changes (P120Q,
F134Y and D144A) and the other harbored the I126N substitution, mutations that might
interfere with HBsAg/anti-HBs binding [39]. Furthermore, multiple point mutations
such as deletions and recombination were discovered in the preS region. Apart from
the preS variants, a number of mutations had also been detected within the ”a” deter-
minant of the major hydrophilic region (MHR) of the surface antigen, against which
natural or vaccine induced neutralizing antibodies are generated [40].
3. Abbreviations
V: vaccine, LMV: lamivudine, HBIG: hepatitis B immunoglobulin, A: alanine, R: arginine,
D: aspartate, C: cystine, F: phenylalanine, G: glycine, H: histidine, I: isolucine, L: lucine,
M: methionine, P: proline, Q: glutamine, R: arginine, S: serine, T: thrionine, W: trypto-
phane, Y: tyrosine.
HBV mutants remain stable over time and their transmission can occur horizontally
or vertically [41]. Missense mutations within the ”a” determinant were responsible
3.5% in 177 restaurant employee in China [42]. The high endimicity areas represent the
most common regions in which vaccine escape mutants were abundant [43]. Monica
et al. reported a case about a Caucasian man who develop acute hepatitis B infection
inspite of having anti-HBs after vaccination, surprisingly this man acquired a mutant
strain with diminished affinity for anti-HBs due to three amino acid substitutions dis-
covered as follows (M125T, T127P and Q129H),these mutations were rarely reported
together [44].
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Amino Acid Position Wild Type Mutant Cause
118 S W HBIG
120 S/P Q/S V-HBIG
125 M T HBIG
127 T P HBIG
128 A V LMV
129 Q H V-HBIG
133 M L/I/T V-HBIG
134 F/Y N/R HBIG
142 P S V
143 S L LMV
144 D A/E V-HBIG
145 G A/R V/LMV/HBIG
182 W S LMV
190 V A LMV
193 S L LMV
195 I M LMV
204 M V/I LMV
T 1: The most studied HBV mutations: wild type, mutant type and the cause of mutations. Done by
the authors [33, 38, 39, 44].
4. Drug Induced Mutations
The desired goal of treatment of CHB infection is to arrest the progression of liver
injury and to improve the quality of life by preventing progression to cirrhosis, HCC
and death. So far, eradication of the virus is impossible and current antiviral treatment
aims to reduce liver failure and HCC and to increase survival,through the effective HBV
DNA suppression [45]. United States Food and Drug Administration (FDA) has approved
six drugs for the treatment of the CHB infection, of these immunomodulator (pegy-
interferon), nucleos(t)ide analogues (lamivudine, enticavir, telbivudine, adifovir and
tenofovir) [46]. Since the ORF encoding HBsAg overlaps with that of the polymerase,
mutations within the former may affect the latter or vice versa, therapy with lamivu-
dine results in several mutations in the polymerase gene, some of them are associated
with alterations in the ‘a’ determinant of HBsAg [47]. Lamivudine is responsible for the
highest rate of resistance reaching up to 70% by year 4 of continuous therapy [48].
Naturally occurring mutations are restricted to the ”a” determinant region, whereas
drug-associated mutations generally occur downstream to the MHR, Kazim et al. has
studied 57 patients with histological proven CHB infection and were on lamivudine
treatment of 100mg/day. Serum samples were taken at base line then after lamivu-
dine therapy, DNA extracted and the region of MHR and flanking area were amplified
and sequenced. The result showed that two patients (3.5%) have naturally occurring
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mutations in the ”a” determinant of the S gene and 24.5% mutations was lamivudine
induced andmainly occurs downstream of theMHR and associated with corresponding
mutations in the polymerase gene. LMV selected mutations downstream of ”a” deter-
minant considered as a cause of decrease in antigenicity of protein and binding to anti-
HBs antibodies. In other recent studies, 8 out of 57 patients developed (rt204I/VDD)
lamivudine resistant polymerase mutant that lead to surface gene mutations such as
sW196Stop, sI195M and sW196L [49, 50].
Gloria Selabe et al. studied 17 patients with chronic hepatitis B infection who
received 150mg/day lamivudine treatment at Johannesburg General Hospital between
1997 and 2004. Mutations in the YMDD region were determined in 13 patients, of those
7 carried rtM204I, 2 of them were hepatitis B e antigen(eAg) positive and 5 with eAg
negative, and the remaining 6 showed rtM204V mutation, 4 eAg positive and 2 eAg
negative. Additionally, the switching from rtM204I to rtM204V was reported in one
patient after 24 months of therapy which indicates that Lamivudine resistance may
develop at similar rates in HBeAg-positive and negative patients [51]. Recently it was
concluded that there is no benefit in continuing lamivudine therapy after emergence
of YMDD mutations [52].
5. Conclusion
The emergence of natural mutations should be expected due to the characteristics
of the HBV genome such as proofreading capacity failure and viral factors such as
the mechanisms of viral production and clearance. The mutations alter the binding of
antibodies developed against wild-type S protein to virions and subviral particles and
it can lead to diagnostic assay failure also. Most patients
with chronic hepatitis B had a good response to Lamivudine therapy but the long
term therapy leads not only to emergence of lamivudine resistance or drug-resistant
polymerasemutants, but also to the appearance of S genemutants and YMDDmutants’
attenuated efficacy of lamivudine treatment. We here propose to develop a vaccine
which includes the most common mutations as well as wild type one and to build a
strategy for the regime of chronic hepatitis B patients such as combination therapy.
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